Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750310 | 0.80 | HRH4 (0.61) | HRH4HRH3CDK1CDK2 | |
| SCHEMBL24309619 | 0.79 | HRH4 (0.59) | HRH4HRH3CDK1CDK2 | |
| SCHEMBL17376493 | 0.79 | CHRM3 (0.40) | HRH4CTSKCTSSKMOL3MBTL1 | |
| SCHEMBL3719255 | 0.76 | HRH4 (0.56) | HRH4HRH3CDK1CDK2 | |
| SCHEMBL7377363 | 0.76 | SMN1; SMN2 (0.41) | HRH3TLR8 | |
| SCHEMBL31003805 | 0.76 | HRH4 (0.46) | HRH4CTSKCTSSKMOL3MBTL1 | |
| SCHEMBL392696 | 0.72 | HRH4 (0.33) | HRH4CTSKCTSSTLR8 | |
| SCHEMBL15534661 | 0.72 | KMO (0.45) | HRH4KMOL3MBTL1ABL1 | |
| SCHEMBL10899837 | 0.71 | POLB (0.34) | HRH4 | |
| SCHEMBL10896284 | 0.71 | POLB (0.34) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | HRH4 1793/4885CTSK 2142/4885CTSS 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.